Daiichi Sankyo

ASCO puts spotlight on advancing antibody-drug conjugate pipeline
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Fierce Pharma
Esperion Therapeutics
Daiichi Sankyo
Nexletol
SEC
Flag link:
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Flag link:
Daiichi torches Esperion’s Nexletol milestone promises
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Daiichi Sankyo
Esperion Therapeutics
Nexletol
Flag link:
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Flag link:
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Daiichi Sankyo
Seagen
PTO
patents
Flag link:
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Endpoints
Daiichi Sankyo
Japan
MRNA
vaccines
drug manufacturing
Flag link:
The first big test for the son of Enhertu
The first big test for the son of Enhertu
EP Vantage
Daiichi Sankyo
Enhertu
datopotamab deruxtecan
clinical trials
Flag link:
Biopharma's stock market winners of 2022 revealed
Biopharma's stock market winners of 2022 revealed
EP Vantage
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Big pharma’s new year catalysts
Big pharma’s new year catalysts
EP Vantage
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Flag link:
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
Flag link:
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Flag link:
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Flag link:
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
Flag link:

Pages